RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Douglas Miehm has reiterated an Outperform rating on Ligand Pharmaceuticals (NASDAQ:LGND) and maintained a price target of $130.
August 12, 2024 | 4:28 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Douglas Miehm has reiterated an Outperform rating on Ligand Pharmaceuticals and maintained a price target of $130.
The reiteration of an Outperform rating and a maintained price target of $130 by a reputable analyst can boost investor confidence in Ligand Pharmaceuticals, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100